Diagnostic performance of microcytic anemia factor in the evaluation of functional iron deficiency in diabetic kidney disease

Authors

  • Pedro Aro Center for Research in Diabetes, Obesity and Nutrition (CIDON), Lima, Peru
  • Christian Lezama Cayetano Heredia Peruvian University, Lima, Peru
  • Dayana Solano Cayetano Heredia Peruvian University, Lima, Peru
  • José Castillo Cayetano Heredia Peruvian University, Lima, Peru
  • Billy Sánchez Jacinto Cayetano Heredia Peruvian University, Lima, Peru
  • Rodrigo Paredes Mount Sinai Beth Israel Hospital, New York, United States
  • Max Acosta Center for Research in Diabetes, Obesity and Nutrition (CIDON), Lima, Peru
  • Helard Manrique Center for Research in Diabetes, Obesity and Nutrition (CIDON), Lima, Peru

DOI:

https://doi.org/10.47196/diab.v58i3.1141

Keywords:

diabetic kidney disease, anemia, type 2 diabetes mellitus, iron metabolism disorders

Abstract

Introduction: measurement of microcytic anemia factor (Maf®) is rapid and cost-effective. Studies demonstrate its usefulness in the study of iron metabolism, however its performance in the diagnosis of functional iron deficiency (FID) is limited.

Objectives: to evaluate the diagnostic performance of Maf® and to establish the cut-off point for early detection of DHF in diabetic kidney disease (DKD).

Materials and methods: cross-sectional study. We included 160 people with a diagnosis of DKD who attended the Diabetes, Obesity and Nutrition Research Center (CIDON) in Lima (Peru) during 2022-2023. A reticulocyte hemoglobin equivalent (Ret-He) value <29 pg was established as a diagnostic criterion for FID. The Maf® was calculated by the formula: Maf® = ([Hb x VCM] /100). The receiver operating characteristic curve (ROC) with the area under the curve (AUC) was used to predict FID.

Results: the frequency of FID was 89.4%. A statistically significant relationship was found between Maf® and FID (p=0.005). ROC curve analysis for Maf® showed an AUC of 0.706 (p=0.001) with a cutoff point of 10.85 (sensitivity 70.59% and specificity of 69.93%) for the detection of DHF in people with DKD.

Conclusions: Maf® has a moderate performance in the identification of FID and could be a potential tool in the screening of patients with DKD.

Author Biographies

Pedro Aro, Center for Research in Diabetes, Obesity and Nutrition (CIDON), Lima, Peru

General Physician, Hemotherapy Service and Blood Bank, Cayetano Heredia National Hospital, Cayetano Heredia Peruvian University

Christian Lezama, Cayetano Heredia Peruvian University, Lima, Peru

Medical Technologist, Clinical Laboratory Specialist

Dayana Solano, Cayetano Heredia Peruvian University, Lima, Peru

Medical Technologist, Clinical Laboratory Specialist

José Castillo, Cayetano Heredia Peruvian University, Lima, Peru

Medical Technologist, Clinical Laboratory Specialist

Billy Sánchez Jacinto, Cayetano Heredia Peruvian University, Lima, Peru

Medical Technologist, Clinical Laboratory Specialist

Rodrigo Paredes, Mount Sinai Beth Israel Hospital, New York, United States

General Practitioner, Internal Medicine Unit

Max Acosta, Center for Research in Diabetes, Obesity and Nutrition (CIDON), Lima, Peru

Physician, specialist in Endocrinology, Endocrinology Service, Delgado AUNA Clinic

Helard Manrique, Center for Research in Diabetes, Obesity and Nutrition (CIDON), Lima, Peru

Physician, specialist in Endocrinology, Endocrinology Service, Delgado AUNA Clinic

References

I. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, et al. Chronic kidney disease. Nat Rev Dis Prim. 2017;3:1-24. doi: 10.1038/nrdp.2017.88.

II. Shalahuddin MS, Mulyaningrum U. Correlation between hemoglobin reticulocytes and ferritin in chronic kidney disease patients undergoing hemodialysis at Pku Bantul Hospital. Berkala Kedokteran 2021;17(2):133-142. doi:10.20527/jbk.v18i1.12843.

III. Organización Panamericana de la Salud, Organización Mundial de la Salud. La OPS/OMS y la Sociedad Latinoamericana de Nefrología llaman a prevenir la enfermedad renal y a mejorar el acceso al tratamiento; 2022. Disponible en: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=10542:2015-opsoms-

IV. Amin AP, Whaley-Connell AT, Li S, Chen SC, McCullough PA, Kosiborod MN, et al. The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2013;61:S12-S23. doi: 10.1053/j.ajkd.2013.01.005.

V. Plataforma digital única del Estado Peruano. Ministerio de Salud. Perú: Gobierno del Perú; 2022. Disponible en: https://www.gob.pe/institucion/minsa/noticias/589662.

VI. Herrera-Añazco P, TaypeRondan A, Lazo-Porras ME, Quintanilla A, Ortiz-Soriano M, Hernández A. Prevalence of chronic kidney disease in Peruvian primary care setting. BMC Nephrology 2017;18:246. doi: 10.1186/s12882-017-0655-x.

VII. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One 2014;9(1):e8494. doi: 10.1371/journal.pone.0084943.

VIII. Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis 2018;71(3):423-435. doi: 10.1053/j.ajkd.2017.09.026.

IX. Dinh NH, Cheanh Beaupha SM, Tran LT. The validity of reticulocyte hemoglobin content and percentage of hypochromic red blood cells for screening iron-deficiency anemia among patients with end-stage renal disease: a retrospective analysis. BMC Nephrol 2020;21(1):142. doi: 10.1186/s12882-020-01796-8.

X. Kamil F, Dhrolia M, Hamid A, Qureshi R, Nasir K, Ahmad A. Frequency of iron deficiency anaemia in chronic kidney disease patient not on dialysis. J Pak Med Assoc 2022;72(7):1396-1400. doi: 10.47391/JPMA.4507.

XI. Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol 2019;142(1):44-50. doi: 10.1159/000496492.

XII. Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy C, Jalal DI. Iron deficiency in chronic kidney disease. Updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol 2020; 31(3):456-468. doi: 10.1681/ASN.2019020213.

XIII. Plastina JCR, Obara VY, Barbosa DS, Morimoto HK, Reiche EMV, Graciano A, et al. Functional iron deficiency in patients on hemodialysis: prevalence, nutritional assessment, and biomarkers of oxidative stress and inflammation. J Bras Nefrol 2019;41(4):472-480. doi: 10.1590/2175-8239-JBN-2018-0092.

XIV. Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant 2021;36(1):129-136. doi: 10.1093/ndt/gfz192.

XV. Bahrainwala J, Berns J. Diagnosis of iron-deficiency anemia in chronic kidney disease. Semin Nephrol 2016;36(2):94-8. doi: 10.1016/j.semnephrol.2016.02.002.

XVI. Toki Y, Ikuta K, Kawahara Y, Niizeki N, Kon M, Enomoto M, et al. Reticulocyte hemoglobin equivalent as a potential marker for diagnosis of iron deficiency. Int. J. Hematol. 2017;106:116-125. doi: 10.1007/s12185-017-2212-6.

XVII. Thomas L, Franck S, Messinger M, Linssen J, Thomé M, Thomas C. Reticulocyte hemoglobin measurement. Comparison of two methods in the diagnosis of iron-restricted erythropoiesis. Clin Chem Lab Med 2005;43:1193-1202. doi: 10.1515/CCLM.2005.207.

XVIII. Jamian E, Sanip Z, Ramli M, Mohd Daud K, Mohamad S, Hassan R. Reticulocyte haemoglobin as a biomarker for the detection of iron deficiency anaemia in haemodialysis patients on recombinant human erythropoietin. J Biomed Clin Sci 2018;3 (2):29-34.

XIX. Singh A, Chaudhary R, Pandey HC, Sonker A. Identification of iron status of blood donors by using low hemoglobin density and microcytic anemia factor. Asian J Transfus Sci 2018;12(1):46-50. doi: 10.4103/ajts.AJTS_30_17.

XX. Dopsaj V, Martinovic J, Dopsaj M. Early detection of iron deficiency in elite athletes: Could microcytic anemia factor (Maf) be useful? Int J Lab Hematol 2014;36:37-44. doi: 10.1111/ijlh.12115.

XXI. Gezgin D, Kaya Z, Bakkaloglu S. Utility of new red cell parameters for distinguishing functional iron deficiency from absolute iron deficiency in children with familial Mediterranean fever. Int J Lab Hematol 2019;41(2):293-7. doi:10.1111/ijlh.12971.

XXII. Urrechaga E, et al. Microcytic anemia factor (Maf) in the study of iron metabolism. Conference: International Society for Laboratory Hematology XXIII Congress At: Brighton UK 2010. doi:10.13140/RG.2.2.28543.00167.

XXIII. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015;372(19):1832-43. doi: 10.1056/NEJMra1401038.

XXIV. Hung SC, Tarng DC. Bone marrow iron in CKD: correlation with functional iron deficiency. American Journal of Kidney Diseases 2010;55(4):617-621. doi: 10.1053/j.ajkd.2009.12.027

XXV. Diebold M, Kistler AD. Evaluation of iron stores in hemodialysis patients on maintenance ferric carboxymaltose dosing. BMC Nephrol 2019;20(1):76. doi: 10.1186/s12882-019-1263-8.

XXVI. Wish JB. Positive iron balance in chronic kidney disease. How much is too much and how to tell? Am J Nephrol 2018;47(2):72-83. doi: 10.1159/000486968.

XXVII. Nguyen Trung K, Ta Viet H, Nguyen Thi Hien H, Nguyen Khanh V, Thai Danh T, Le Viet T. Evaluation of predicting the value of the reticulocyte hemoglobin equivalent for iron deficiency in chronic kidney disease patients. Nephro-Urol Mon 2022;14(2):e121289. doi: 10.5812/numonthly-121289.

XXVIII. Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care 2009;32(7):1320-6. doi: 10.2337/dc08-0779.

XXIX. Karagülle M, Aksu Y, Vetem I, Akay O. Clinical significance of the new Beckman-Coulter parameters in the diagnosis of iron deficiency snemia. Eskisehir Med J 2022; 3(3):292-296 doi: 10.48176/esmj.2022.88.

XXX. Capel-Casbas M, Diaz J, Duran J, Ruíz G, Símon R, Rodríguez F, et al. Latent iron metabolism disturbances in fertile women and its detection with the automated hematology instrument LH750®. Blood 2005;106(11):3707. doi: 10.1182/blood.V106.11.3707.3707.

XXXI. Bart AM, Balvers MG, Hopman MT, Eijsvogels TM, Gunnewiek JM, van Kampen CA. Reticulocyte hemoglobin content in a large sample of the general Dutch population and its relation to conventional iron status parameters. Clinica Chimica Acta 2018;483:20-24. doi: 10.1016/j.cca.2018.04.018.

Downloads

Published

2024-09-17

How to Cite

Aro, P., Lezama, C., Solano, D., Castillo, J., Sánchez Jacinto, B., Paredes, R., Acosta, M., & Manrique, H. (2024). Diagnostic performance of microcytic anemia factor in the evaluation of functional iron deficiency in diabetic kidney disease. Journal of the Argentine Society of Diabetes, 58(3), 125–131. https://doi.org/10.47196/diab.v58i3.1141

Issue

Vol. 58 No. 3 (2024): September-December 2024

Section

Original article

License

Copyright (c) 2024 on behalf of the authors. Reproduction rights: Argentine Society of Diabetes

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.